ArticleFrontiers in medicine2026
Vascular norepinephrine responsiveness index for early risk stratification in emergency department septic shock: a real-world cohort study from a Latin American sepsis code registry.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Septic shock is characterized by heterogeneous vascular responsiveness to norepinephrine. The vascular norepinephrine responsiveness index (VNERi), calculated as diastolic arterial pressure divided by the product of norepinephrine dose and heart rate, has been proposed as a bedside risk-stratification marker. Its performance in routine emergency department care remains uncertain. Methods: We conducted a single-center retrospective cohort study of adults with septic shock treated with norepinephrine in the emergency department from 2023 to 2025. The index time was the first protocolized invasive hemodynamic assessment after norepinephrine initiation. The primary outcome was 28-day in-hospital mortality. Logistic regression evaluated the association between VNERi and mortality, adjusting for age, Sequential Organ Failure Assessment score, Charlson comorbidity index, and serum lactate. Discrimination was compared with that of the mean arterial pressure-to-norepinephrine dose ratio (MAP/NE) using paired receiver operating characteristic curves. Non-linearity was assessed using restricted cubic splines. The previously reported value of 6.7 and a cohort-specific cutoff derived using the Youden index were explored. Results: Among 238 patients, 70 experienced 28-day in-hospital mortality. Median age was 72 years, 52.9% were female, median Charlson comorbidity index was 4, and mean Sequential Organ Failure Assessment score was 7.4. Each 1-unit increase in VNERi was independently associated with lower odds of mortality (adjusted odds ratio, 0.85; 95% CI, 0.79-0.91). VNERi showed modestly greater discrimination than MAP/NE (AUROC, 0.737 [95% CI, 0.675-0.799] vs. 0.667 [95% CI, 0.592-0.742]; Conclusions: Lower VNERi was independently associated with higher 28-day in-hospital mortality and showed modestly greater discrimination than MAP/NE. Prospective multicenter validation using standardized measurement timing and external validation of candidate thresholds are required before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.